A Phase II Multi-Center Safety Study Examining the Use of the O'Neil Long Acting Naltrexone Implant (OLANI) in Opioid Dependent Persons Receiving Repeat Dosing

This study will examine the safety and efficacy of the O'Neil Long Acting Naltrexone Implant (OLANI) in persons with opioid dependency who are seeking relapse-prevention treatment. All participants will be treated in an open label manner. No randomization will occur. The OLANI is a long-acting biodegradable form of naltrexone which is implanted in the abdominal region. It is hypothesized that the OLANI will produce blood levels sufficient to block the effects of opioids for an extended period allowing patients to engage in psychosocial treatment and recovery over the long term. After the initial set of implants, participants will be offered 3 sets of single implants 13 weeks, each with an acceptable window of 12-16 weeks after the previous dose.

开始日期2026-07-15

申办/合作机构

Go Medical Industries Pty Ltd.

[+5]

NCT07398404

/ Not yet recruiting临床1/2期IIT

A Multiple Health Behavior Change Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients

The purpose of this research study is to evaluate a multiple health behavior change intervention for weight loss and smoking cessation using medication (Naltrexone + Bupropion) and behavior therapy in adults seeking bariatric surgery. The intervention will be compared to a standard of care control group.

开始日期2026-07-01

申办/合作机构

Yale University

[+1]

NCT07285473

/ Not yet recruiting临床2期IIT

Low-dose Naltrexone (LDN) for the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Dose-Finding

This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A remote trial approach is used, with eligibility open to the state of Alabama.

开始日期2026-04-01

申办/合作机构

The University of Alabama at Birmingham

100 项与盐酸纳曲酮相关的临床结果

登录后查看更多信息

100 项与盐酸纳曲酮相关的转化医学

登录后查看更多信息

100 项与盐酸纳曲酮相关的专利（医药）

登录后查看更多信息

3,576

项与盐酸纳曲酮相关的文献（医药）

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Hailey-Hailey disease successfully treated with naloxone: 2 case reports and Review of the literature on efficacy of opioid receptor antagonist in Hailey-Hailey disease patients

Review

作者: Zhimin Duan ; Chengrang Li ; Fang Fang ; Jianbing Wu ; Beilei Xu ; Hao Song ; Junyou Zheng ; Nan Sheng

BACKGROUND:

Hailey-Hailey disease (HHD), a genetic blistering disease, is caused by a mutation in a calcium transporter protein in the Golgi apparatus encoded by the ATP2C1 gene. Clinically, HHD is characterized by flaccid vesicles, blisters, erosions, fissures, and maceration mainly in intertriginous regions. Some patients remain refractory to conventional treatments. Previously, a series of reports have confirmed naltrexone as an effective option for those patients. However, in China, naltrexone is unavailable in some hospitals and unaffordable for some patients.

OBJECTIVE:

To confirm naloxone as a treatment option for HHD, and assess the efficacy rate and safety of naltrexone for patients with HHD.

METHODS:

Two patients with biopsy-proven HHD received naloxone (2 mg/d, via intravenous infusion). We followed up with the two patients, assessing the change of skin lesions and obtaining photographs. We searched the PubMed databases using the keywords 'Hailey-Hailey disease' or 'benign familial pemphigus', and 'naltrexone' or 'naloxone', and reviewed English publications of reports and analyzed the efficacy and safety of naltrexone.

RESULTS:

Two patients prescribed naloxone showed completely remission in two weeks without any adverse reactions. The total remission rate of naltrexone for HHD is approximately 80%, without severe adverse effects.

CONCLUSION:

Naltrexone is effective and safe in the treatment of HHD. Naloxone, an analog of naltrexone, can also effectively and safely treat HHD, potentially offering a new therapeutic option for patients with refractory HHD.

2025-12-01·JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Low Dose Naltrexone for Refractory Cancer Pain: Case Series of Initial Safety and Effectiveness

Article

作者: Chung, Matthew ; Malik, Aila ; Ye, Alice

CONTEXT:

Low dose naltrexone (LDN) has been utilized off-label for chronic non-cancer pain; its benefits in treating cancer-related pain remain unclear.

OBJECTIVES:

We describe the safety and effectiveness of LDN therapy from initiation to the first two follow-up visits in treating refractory cancer-pain.

METHODS:

Medical charts of cancer patients seen in the Pain Management Center who were prescribed LDN between 2022 and 2023 were reviewed. They were classified as "responders" if they attributed improvement in their primary pain complaints to LDN therapy.

RESULTS:

Among the 20 cancer patients who were prescribed LDN, the most common cancer diagnosis was breast cancer (45%). There were 10 patients with cancer burden-related pain and 10 patients with therapy-related pain. Positive response rates of 80% (16/20), and 76.9% (10/13) were recorded at the first and second follow-up visits, respectively which occurred at a mean (SD) of 65.9 (53.3), and 104.8 (60.4) days following LDN initiation, respectively. The most common maximum titration dose of naltrexone was 3.0 mg daily (n = 9) (range 1.5-4.5 mg daily). Therapy-related neuropathy accounted for seven cases with a 71% positive response rate in this subset at the first follow-up. Minor adverse events were noted in two patients (insomnia, GI upset) at the first follow-up; these did not require discontinuation of LDN. The discontinuation rate by the second follow-up was 15% (3/20) (two with inadequate pain relief, one with diarrhea).

CONCLUSION:

Early follow-up indicates potential benefits for patients with refractory cancer pain with LDN being well-tolerated, with a low incidence of adverse events.

2025-12-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Intramolecular hydrogen-bonding motifs in the 14-oxymorphinan opioids: An experimental and computational study

Article

作者: Yeffet, Dina ; Pevzner, Alexander ; Parvari, Galit ; Elias, Shlomi ; Zafrani, Yossi ; Eichen, Yoav ; Columbus, Ishay ; Lifshin-Karton, Naama ; Saphier, Sigal ; Cohen, Yoram

Increasing the molecular rigidity of bioactive compounds by intramolecular hydrogen bonds (IMHB) may affect both pharmacodynamics (PD) and pharmacokinetics (PK) by an increase in molecular recognition, lipophilicity and membrane permeability. Recently, in our study on opioids lipophilicity, we suggested two types of IMHBs, i.e., O-H⋯N and N⁺-H^…O, which may exist in 14-oxymorphinan structures and may explain some trends and even apparent anomalies in their pharmacologically relevant molecular properties. In the present study we show, both experimentally and computationally, that these IMHBs indeed exist in the three FDA-approved opioid antagonists, Naloxone, Naltrexone and Nalmefene, as well as in their 3-O- and 14-O-methylated derivatives. Since the charged form of these morphinans is the biologically active species, we propose that the charge-assisted IMHB (CAHB) N⁺-H^…O, which is herein studied for the first time, plays an important role in the bioactivity of this subfamily of opioids.

237

项与盐酸纳曲酮相关的新闻（医药）

2026-03-11

·biocorrx.com

BioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant Technology

Issued Patent Supports BioCorRx's Growing Portfolio of Implant-based Naltrexone Technologies ANAHEIM, CA - March 11, 2026 (NEWMEDIAWIRE) - BioCorRx Inc. (OTC: BICX) (the "Company"), a developer and provider of innovative treatment support programs for substance abuse and related disorders, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,569,430, entitled "Biodegradable Implant Including Naltrexone." The patent is assigned to BioCorRx, Inc. and relates to biodegradable implant technology designed to provide controlled delivery of naltrexone. The newly issued patent strengthens the Company's intellectual property portfolio relating to naltrexone-based implant technologies. The Company's broader portfolio also includes issued international patents covering additional technologies and potential therapeutic applications involving naltrexone implants, including an Israeli patent relating to the use of a naltrexone implant in weight management programs when combined with behavioral or nutritional counseling. The Company continues to pursue additional patent protection in the United States and internationally relating to its implant-based naltrexone technologies. BioCorRx continues to advance development of its implant-based naltrexone technologies through its majority owned subsidiary, BioCorRx Pharmaceuticals, Inc. A prior clinical study evaluating the Company's implant technology was completed in 2023. A new clinical study commenced in January 2026, with additional studies planned. "The issuance of this patent represents an important milestone for BioCorRx and further strengthens our growing intellectual property portfolio relating to implant-based naltrexone technologies," said Lourdes Felix, Chief Executive Officer of BioCorRx Inc. "As we continue advancing development of our implant technology through BioCorRx Pharmaceuticals Inc., we believe continued expansion of our patent portfolio supports our long-term strategy around implant-based therapeutic technologies." About BioCorRx Inc. BioCorRx Inc. (OTC: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx® Weight Loss Program is also a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts, and personal support from behavioral experts, please visit www.uncraverx.com for more information on UnCraveRx®. BioCorRx also operates through its subsidiary, BioCorRx Pharmaceuticals Inc., which focuses on pharmaceutical commercialization and development, including LUCEMYRA® (lofexidine) - an FDA-approved medication indicated to mitigate opioid withdrawal symptoms in adults - and the development of BICX104, an investigational implantable naltrexone pellet program. For more information on BICX and its subsidiary pipeline, please visit www.BioCorRx.com. About BICX104 BICX104 is BioCorRx's investigational biodegradable naltrexone implant technology designed to provide controlled delivery of naltrexone. A prior clinical study evaluating the Company's implant technology was completed in 2023 (ClinicalTrials.gov Identifier: NCT04828694). A new clinical study evaluating BICX104 commenced in January 2026 (ClinicalTrials.gov Identifier: NCT07269873), with additional studies planned. The current clinical study is supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health under Award Number U01DA059994. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Prior research evaluating the Company's implant technology was also supported in part by the National Institute on Drug Abuse. About Naltrexone Naltrexone is an opioid receptor antagonist that blocks the effects of opioids at the mu-opioid receptor. It has been approved by the U.S. Food and Drug Administration (FDA) in oral and extended-release injectable forms for the treatment of opioid use disorder and alcohol dependence. By blocking opioid receptors, naltrexone can prevent the euphoric and sedative effects of opioids. Naltrexone has also been studied for potential use in other conditions, including substance use and metabolic disorders. About MUD Methamphetamine Use Disorder (MUD) is a serious and growing public health concern. Methamphetamine is a highly addictive central nervous system stimulant that can have significant health consequences. According to the 2023 National Survey on Drug Use and Health (NSDUH), approximately 2.6 million people in the United States aged 12 or older reported using methamphetamine in the past year, and 1.6 million people met the criteria for methamphetamine use disorder. Methamphetamine misuse has been associated with a range of adverse health effects, including severe dental disease, cognitive impairment, psychiatric symptoms such as anxiety and psychosis, and damage to the cardiovascular system. Lifetime methamphetamine use has been reported by more than 16 million people in the United States, according to the National Survey on Drug Use and Health. About OUD Opioid Use Disorder (OUD) is a chronic and relapsing medical condition characterized by the problematic use of opioid drugs despite harmful consequences. Opioids are medications commonly prescribed for pain relief that act on the central nervous system and may produce both analgesic effects and feelings of euphoria. OUD can develop through misuse of prescription opioid medications, use of diverted prescription opioids, or use of illicit opioids such as heroin or illegally manufactured fentanyl. According to the 2023 National Survey on Drug Use and Health, approximately 5.7 million people in the United States aged 12 or older were estimated to have an opioid use disorder in the past year. OUD is associated with significant health risks, including overdose, infectious diseases, and increased rates of morbidity and mortality. About Obesity Obesity is a growing global public health concern. According to the World Health Organization, approximately 890 million adults worldwide were living with obesity in 2022, representing about 1 in 8 people globally. Worldwide adult obesity has more than doubled since 1990, and adolescent obesity has quadrupled during that time. The World Obesity Federation projects that over 1.5 billion adults could be living with obesity by 2035, and that more than half of the global population, over 4 billion people, may be living with overweight or obesity if current trends continue. The global economic impact of overweight and obesity is projected to exceed $4 trillion annually by 2035, driven by obesity-related conditions such as cardiovascular disease, stroke, cancer, and type 2 diabetes. About LUCEMYRA® (lofexidine) LUCEMYRA® (lofexidine), an oral tablet, is a central alpha 2-adrenergic agonist that reduces the release of norepinephrine to suppress the neurochemical surge that produces opioid withdrawal. It is indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. In clinical trials, LUCEMYRA® reduced the severity of withdrawal symptoms compared to placebo, as reported by patients experiencing opioid withdrawal. LUCEMYRA® is administered orally for up to 14 days, with dosing guided by symptoms. LUCEMYRA® should be discontinued with gradual dose reduction over two to four days. The most common adverse reactions are orthostatic hypotension, bradycardia, hypotension, dizziness, somnolence, sedation, and dry mouth. Forward-Looking Statements This press release contains forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Important Safety Information What is LUCEMYRA? LUCEMYRA is a non-opioid prescription medicine used in adults to help with the symptoms of opioid withdrawal that may happen when you stop taking an opioid suddenly. LUCEMYRA will not completely prevent the symptoms of opioid withdrawal and is not a treatment for opioid use disorder. LUCEMYRA can cause serious side effects, including low blood pressure, slow heart rate, and fainting. Watch for symptoms of low blood pressure or heart rate, including dizziness, lightheadedness, or feeling faint at rest or when quickly standing up; if you experience these symptoms, call your healthcare provider right away and do not take your next dose of LUCEMYRA until you have talked to your healthcare provider. Avoid becoming dehydrated or overheated and be careful not to stand up too suddenly from lying or sitting, as these may increase your risk of low blood pressure and fainting. When your treatment is complete, you will need to stop taking LUCEMYRA gradually, or your blood pressure could increase. After a period of not using opioid drugs, you can become more sensitive to the effects of opioids if you start using them again. This may increase your risk of overdose and death. Before taking LUCEMYRA, tell your healthcare provider about all your medical conditions, including if you have low blood pressure, slow heart rate, any heart problems including history of heart attack or a condition called long QT syndrome, liver or kidney problems, or if you drink alcohol. Tell your healthcare provider if you are pregnant, plan on becoming pregnant, or are breastfeeding; it is not known if LUCEMYRA can harm your unborn baby or whether LUCEMYRA passes into your breast milk. Especially tell your healthcare provider if you take benzodiazepines, barbiturates, tranquilizers, or sleeping pills, as taking these with LUCEMYRA can cause serious side effects. The most common side effects of LUCEMYRA include low blood pressure or symptoms of low blood pressure such as lightheadedness, slow heart rate, dizziness, sleepiness, and dry mouth. To report SUSPECTED ADVERSE REACTIONS or product complaints, contact BioCorRx Pharmaceuticals Inc. at 1-833-LUCEMYRA. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Click here to see full Prescribing Information. BioCorRx Inc. info@BioCorRx.com 714-462-4880 Investor Relations: Crescendo Communications, LLC 212- 671-1020 x304 bicx@crescendo-ir.com View the original release on www.newmediawire.com Released March 11, 2026

上市批准临床结果

2026-02-24

·EINPresswire

Expanded care and telehealth bring opioid addiction treatment to southern New Mexico families

New outpatient and telehealth initiatives increase access to evidence-based recovery resources for families and individuals across southern New Mexico. ALAMOGORDO, NM, UNITED STATES, February 24, 2026 / EINPresswire.com / -- As communities across New Mexico continue to feel the impact of the opioid crisis, Renew Health Addiction Recovery Services is strengthening its commitment to accessible, effective care by enhancing its opioid medication-assisted treatment options in Alamogordo . Through a combination of outpatient services and secure telehealth care, Renew Health is expanding support for individuals seeking a safer, more sustainable path to recovery. Renew Health’s approach to opioid use disorder is rooted in evidence-based care that treats addiction as a medical condition, one that requires consistency, compassion, and personalized support. At its Alamogordo location, patients have access to Medication-Assisted Treatment (MAT), which pairs FDA-approved medications such as buprenorphine and naltrexone with therapy and behavioral health services. This integrated model helps reduce cravings and withdrawal symptoms while addressing the underlying mental and emotional factors tied to substance use. “Opioid addiction doesn’t look the same for everyone, and recovery shouldn’t either,” said a Renew Health representative. “By expanding our opioid medication-assisted treatment options in Alamogordo, we’re making it easier for people to access care that fits their lives and supports long-term recovery, not just short-term stabilization.” The Alamogordo clinic plays an important role in Renew Health’s broader mission to close treatment gaps across New Mexico, particularly in communities where access to addiction care has historically been limited. With no overnight stays and no long waitlists, Renew Health’s outpatient model allows individuals to receive consistent treatment while remaining connected to their families, work, and support systems. Every patient who enters Renew Health begins with a comprehensive assessment designed to understand their health history, substance use patterns, and personal goals. From there, the care team develops a customized treatment plan that may include medication management, Cognitive Behavioral Therapy (CBT), mental health counseling , and family involvement when appropriate. This whole-person approach recognizes that recovery is not just about stopping substance use, but about rebuilding stability, confidence, and daily functioning. Telehealth services further expand access to care for residents in and around Alamogordo, offering secure online appointments for medication management and therapy. This flexibility helps remove barriers such as transportation challenges, work schedules, or distance, making treatment more attainable for individuals who might otherwise delay or avoid care. Renew Health’s clinical team is led by board-certified addiction specialists and experienced medical professionals who are deeply committed to patient-centered care. Founded by Nurse Practitioner Trent Carter, the organization was built with a clear purpose: to provide respectful, evidence-based addiction treatment in communities that need it most. The organization’s commitment to quality has earned statewide recognition. Renew Health was named the “Best Drug and Alcohol Rehab Center in New Mexico in 2024” by Addiction Group, an acknowledgment that reflects both strong clinical standards and meaningful patient outcomes. “We see the impact addiction has on families every day,” the representative added. “Our goal is to offer real solutions - care that is medically sound, emotionally supportive, and accessible when people are ready to take that first step.” Individuals seeking opioid addiction treatment in Alamogordo can learn more about Renew Health’s services by contacting the team directly at (575) 363-3189 or 575-363-HELP, or by emailing info@renewhealth.com. Appointments are available Monday through Friday, 9 a.m. to 5 p.m. ### About Renew Health Addiction Recovery Services: Renew Health Addiction Recovery Services provides outpatient and telehealth addiction treatment for individuals across New Mexico. The organization specializes in Medication-Assisted Treatment (MAT), mental health services, and evidence-based therapy for substance use disorders, including opioid and alcohol addiction. Led by board-certified addiction specialists, Renew Health focuses on reducing barriers to care and delivering personalized, compassionate treatment that supports long-term recovery. With clinic locations in Roswell, Alamogordo, and Clovis, Renew Health is dedicated to rebuilding lives and strengthening communities throughout the state. Trent Carter Renew Health +1 575-363-4357 email us here Visit us on social media: Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2026-01-30

·GlobeNewswire-Health Care

Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets

PALO ALTO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has made a $20 million strategic investment in Quantum Scan Holdings, Inc. (“Quantum Scan”), a breakthrough medical technology company, targeting trillion-dollar market of preventive diagnosis and prognosis of human diseases and illness. The investment is intended to support Quantum Scan’s ongoing efforts to identify, develop, and deploy innovative medical technologies, including advanced diagnostic platforms, integrated analytics, and scalable healthcare solutions designed to improve accessibility and efficiency across clinical and non-traditional care settings. Scilex believes this strategic investment is synergistic with its large investment in Datavault AI (Nasdaq: DVLT) (“Datavault”). Mustaq Patel, Chief Executive Officer of Quantum Scan, stated: “We are grateful to Scilex for their strategic investment and confidence in our team and vision. The need for continued innovation in medical technologies has never been greater. This capital enables Quantum Scan to accelerate its focus on forward-looking healthcare solutions and to invest in technologies that we believe can deliver long-term value and meaningful impact across the healthcare ecosystem.” Henry Ji, Ph.D., Chairman and Chief Executive Officer of Scilex Holding Company, commented: “Quantum Scan is led by an experienced team with a clear focus on innovation, revenue-generation, disciplined execution, and potential large long-term value creation. We believe this investment complements Scilex’s strategic priorities and provides an opportunity to support the development of innovative medical technology platforms aligned with our broader commitment to advancing healthcare solutions.” For more information on Scilex Holding Company, refer to www.scilexholding.com For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com. For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com. For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com. https://www.facebook.com/scilex.pharm https://www.linkedin.com/company/scilex-holding-company/ info@scilexholding.com About Scilex Holding Company Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia. Scilex is headquartered in Palo Alto, California. About Quantum Scan Holdings, Inc. Quantum Scan Holdings, Inc. is a medical technology and innovation company focused on the development and investment in advanced healthcare technologies. Quantum Scan’s activities include medical platforms, diagnostics, analytics, and related innovations aimed at enhancing healthcare delivery, accessibility, and clinical insight. Forward-Looking Statements This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, Quantum Scan’s prospects, plans and goals, Scilex’s intellectual property goals and processes, future opportunities for Scilex and its subsidiaries, the future business strategies, long-term objectives and commercialization plans of Scilex and its subsidiaries, the current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity of Scilex and its subsidiaries, statements regarding SP-102, if approved by the FDA, Scilex’s potential to attract new capital and avoid the effects of negative debt leverage and other statements that are not historical facts. These statements are based on management’s current expectations and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business, Quantum Scan’s business and Datavault’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political and business conditions; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; the risk of failure to realize the anticipated benefits of the transactions contemplated with Datavault and Quantum Scan and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements. Contacts: Investors and MediaScilex Holding Company 960 San Antonio RoadPalo Alto, CA 94303Office: (650) 516-4310 Email: investorrelations@scilexholding.com Website: www.scilexholding.com SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned. ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company. Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company. ELYXYB® is a registered trademark owned by Scilex Holding Company. Scilex Bio™ is a trademark owned by Scilex Holding Company, Inc. All other trademarks are the property of their respective owners. © 2026 Scilex Holding Company All Rights Reserved.

上市批准快速通道临床3期临床2期

100 项与盐酸纳曲酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02095	盐酸纳曲酮	N07BB04	DB00704

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
鸦片依赖	中国	深圳善康医药科技股份有限公司	2024-06-25
海洛因依赖	澳大利亚	Generic Health Pty Ltd.	2007-08-31
酗酒	美国	Teva Women's Health, Inc.	1984-11-20
阿片相关性障碍	美国	Teva Women's Health, Inc.	1984-11-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
酒精使用障碍	临床3期	中国	深圳善康医药科技股份有限公司	2026-02-04
未指明的药物依赖	临床3期	美国	Alkermes, Inc.	2010-05-01
克罗恩病	临床2期	美国	Hershey Medical Center	2006-09-01
炎症	临床2期	美国	Hershey Medical Center	2006-09-01
新型冠状病毒感染	临床1期	美国	Statera Biopharma, Inc.	2021-12-05
炎症性肠病	临床前	中国	深圳善康医药科技股份有限公司	2024-09-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04791969 (CTgov)	临床2期	-	60	Ecological Momentary Intervention+Naltrexone Hydrochloride (Naltrexone With Ecological Momentary Intervention)	衊繭願願鹽積糧選繭壓 = 鑰積醖構膚憲築憲夢築窪夢廠襯簾廠膚壓選鏇 (淵膚構醖醖壓繭鏇範衊, 觸齋繭醖艱網鬱糧鬱製 ~ 衊鏇齋築鹽壓壓廠鹹鬱) 更多	-	2025-10-27
				Placebo (Placebo With Ecological Momentary Intervention)	衊繭願願鹽積糧選繭壓 = 願選糧簾願鏇願選繭壓窪夢廠襯簾廠膚壓選鏇 (淵膚構醖醖壓繭鏇範衊, 鹹築壓網淵衊簾夢製衊 ~ 鏇網網蓋餘製壓糧齋遞) 更多
NCT05073679 (ONPED, CTgov)	临床2/3期	暴食症 \| 神经性贪食症 \| 非典型神经性厌食 ... 更多	9	Naltrexone Hydrochloride (Intervention)	壓憲襯憲齋淵選壓膚構(齋鑰夢築餘願顧願窪鏇) = 廠網醖壓願鏇觸遞鬱壓淵襯餘獵憲壓艱餘繭壓 (淵醖願鑰製網繭餘襯醖, 2.016184515) 更多	-	2025-08-19
				Control (Control)	壓憲襯憲齋淵選壓膚構(齋鑰夢築餘願顧願窪鏇) = 選製膚網積蓋齋獵鏇積淵襯餘獵憲壓艱餘繭壓 (淵醖願鑰製網繭餘襯醖, 0.871779789) 更多
NCT03647774 (Pubmed \| Addict Sci Clin Pract)	临床4期	阿片滥用	129	extended-release naltrexoneXR-NTX naltrexone (Completed XR-NTX induction)	鑰構鑰艱淵糧壓鹹構窪(夢選願鹹顧範構獵壓範) = 鹹獵鏇齋廠構獵鏇淵襯顧構構築選襯築獵鑰獵 (願顧憲齋衊鏇網選獵艱 ) 更多	积极	2025-06-16
				extended-release naltrexoneXR-NTXtrexone (Non-completed XR-NTX induction)	鑰構鑰艱淵糧壓鹹構窪(夢選願鹹顧範構獵壓範) = 壓蓋淵鬱醖觸鑰膚遞廠顧構構築選襯築獵鑰獵 (願顧憲齋衊鏇網選獵艱 ) 更多
NCT02478489 (ADOPT, Pubmed \| JAMA Intern Med)	临床4期	酒精使用障碍	248	Oral Naltrexone	簾衊顧觸簾鑰淵鏇積築(構衊繭觸繭範醖獵艱醖): adjusted odds ratio = 1.34 (95% CI, 0.77 ~ 2.33)	-	2025-06-01
				Extended-Release Injectable Naltrexone
NCT02461927 (CTgov)	临床1/2期	酒精使用障碍 \| 重度抑郁症	65	Naltrexone+Ketamine (Ketamine + Naltrexone)	廠鏇廠鬱憲鏇衊顧艱夢 = 憲選鏇構構願廠艱夢鬱憲夢鑰艱鬱襯繭積範鑰 (壓齋餘鬱觸選築簾繭遞, 齋窪淵窪夢憲獵繭鏇築 ~ 壓鑰齋願範鹹襯鹹簾顧) 更多	-	2025-04-10
				Placebo+ketamine (Ketamine + Placebo)	廠鏇廠鬱憲鏇衊顧艱夢 = 遞鏇膚顧窪願醖餘鹽糧憲夢鑰艱鬱襯繭積範鑰 (壓齋餘鬱觸選築簾繭遞, 蓋鬱製築餘製鏇鏇積鑰 ~ 範艱窪觸廠選選鬱築廠) 更多
NCT04313972 (CTgov)	临床4期	间质性膀胱炎 \| 疼痛	3	low-dose naltrexone (Low-dose Naltrexone)	衊衊繭鏇糧選鹽繭繭夢 = 繭鹽顧鹹襯遞觸網糧繭憲構範鏇觸窪艱遞鬱築 (獵觸憲鏇齋齋繭範淵網, 選艱築鑰齋積餘獵窪積 ~ 積築獵遞壓鹽網獵繭鬱) 更多	-	2025-03-07
				Placebo oral tablet (Placebo)	衊衊繭鏇糧選鹽繭繭夢 = 簾艱廠獵鏇獵願壓製蓋憲構範鏇觸窪艱遞鬱築 (獵觸憲鏇齋齋繭範淵網, 艱繭齋艱壓憲襯獵製艱 ~ 獵廠憲衊蓋衊網鏇淵鏇) 更多
NCT04139668 (CTgov)	临床2期	大麻戒断	1	Motivational Enhancement Therapy and Cognitive Behavioral Therapy+Naltrexone 380 MG [Vivitrol]	膚顧夢獵製衊選夢餘積 = 積積遞構築衊遞襯膚鏇觸窪醖鏇遞蓋襯餘糧鏇 (襯觸夢遞夢鹹廠壓鏇繭, 醖夢憲蓋獵鹽蓋製選選 ~ 醖艱夢鹹蓋鏇鹹夢獵顧) 更多	-	2025-02-07
NCT04854551 (CTgov)	临床1/2期	-	13	Naltrexone (Naltrexone)	醖簾齋顧遞憲憲餘製糧(餘遞壓衊艱醖鹽願鏇衊) = 襯獵鹹鬱鹽鏇鹽鏇齋糧醖鹽觸襯淵鏇範鹹範襯 (鬱製鑰選膚鑰鏇蓋製選, 0.09) 更多	-	2023-11-28
				Placebo (Placebo)	醖簾齋顧遞憲憲餘製糧(餘遞壓衊艱醖鹽願鏇衊) = 壓憲窪廠糧簾顧網網膚醖鹽觸襯淵鏇範鹹範襯 (鬱製鑰選膚鑰鏇蓋製選, 0.10) 更多
NCT04935931 (EDIT-N2, CTgov)	早期临床1期	暴食症 \| 喂食及进食障碍	13	Naltrexone	積製憲餘範衊鬱夢淵夢(獵鬱膚獵鑰構餘遞範憲) = 壓廠簾膚壓遞憲網鹽選繭願築顧鏇餘糧餘膚鏇 (鹹夢製鏇窪艱艱築獵齋, 0.03) 更多	-	2023-08-21
NCT04756128 (COLTREXONE, CTgov)	临床2期	新型冠状病毒感染	142	Colchicine 0.6 mg (Colchicine-Only Arm)	膚製築選範積範鏇築餘 = 簾鹹艱觸糧繭積鬱艱廠淵襯鹽顧範艱觸鏇簾鑰 (糧簾構糧鬱選鑰餘選顧, 積製憲淵遞鏇鏇獵觸糧 ~ 簾製顧壓夢觸簾鏇願獵) 更多	-	2023-07-25
				Naltrexone+Colchicine 0.6 mg (Colchicine and Naltrexone ("Combined") Arm)	膚製築選範積範鏇築餘 = 願齋選糧蓋觸願鹽廠艱淵襯鹽顧範艱觸鏇簾鑰 (糧簾構糧鬱選鑰餘選顧, 範淵觸網獵鹹範蓋簾鹽 ~ 遞製積選艱艱壓鹽鏇製) 更多